Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance

This study has been completed.
DBL -Institute for Health Research and Development
Information provided by (Responsible Party):
Brian Greenwood, London School of Hygiene and Tropical Medicine Identifier:
First received: August 31, 2005
Last updated: January 11, 2017
Last verified: January 2017

Plasmodium falciparum resistance to chloroquine (CQ) and sulfadoxine-pyrimethamine (SP) continue to spread, impeding control of this important disease. CQ and SP are still the most commonly used antimalarial drugs for malaria prevention during pregnancy and might be made less effective by resistance. However, the treatment and prophylaxis regimens used may also create conditions for selecting resistant malaria parasite strains. A better understanding of the relationships between chemoprophylaxis regimens and resistance would be helpful to improve chemoprophylaxis of malaria in pregnancy.

This work aims to improve the use of chemoprophylaxis in pregnancy by determining whether there is a relationship between the use of standard prophylactic regimens with CQ and SP and the occurrence of P. falciparum resistant strains in pregnant women. The study consists of 2 parts. The first part is a randomized trial comparing 3 chemoprophylactic treatment groups: - weekly CQ after initial presumptive CQ treatment, - CQ intermittent presumptive treatment given as a standard dose at 2nd and 3rd trimester, respectively and SP intermittent presumptive treatment given as a single dose at 2nd and 3rd trimester, respectively. These treatment groups will also be compared to a group of women delivering at the same health centre but who have not been participating in the study. The second part will be a clinical trial for assessment of clinical and parasitological efficacy of CQ and SP treatment in pregnant women presenting with uncomplicated malaria attacks.

The study will be conducted from October 2002 to March 2005 in a health centre of Ouagadougou, Burkina Faso where malaria transmission is seasonal and resistance to CQ and SP is low.

Condition Intervention
Malaria in Pregnancy
Birth Weight
Drug: sulphadoxine-pyrimethamine
Drug: chloroquine

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Single Group Assignment
Masking: Single Blind
Primary Purpose: Treatment
Official Title: Relationships Between the Use of Antimalarial Drugs in Pregnancy and Plasmodium Falciparum Resistance

Resource links provided by NLM:

Further study details as provided by London School of Hygiene and Tropical Medicine:

Primary Outcome Measures:
  • See detailed description

Secondary Outcome Measures:
  • see detailed description

Estimated Enrollment: 700
Study Start Date: October 2002
Study Completion Date: March 2008
Primary Completion Date: June 2007 (Final data collection date for primary outcome measure)
  Show Detailed Description


Ages Eligible for Study:   15 Years to 49 Years   (Child, Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes

Inclusion Criteria:

  • primi or secundigravidae - seen between 12th and 24th weeks of gestation

    • with a non 'at risk pregnancy' (multiple pregnancy, obstetric misproportions, previous caesarean, high blood pressure, diabetes, clinical signs of AIDS.
    • staying in a neighbouring district or village
    • ability to come for follow-up and delivery.

Exclusion Criteria:

  • • At risk pregnancy

    • Severe systemic disease
    • Wish to withdraw from participation.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00140517

Burkina Faso
Centre Medicale Paul VI
Ouagadougou, Burkina Faso, 01-2099
Sponsors and Collaborators
London School of Hygiene and Tropical Medicine
DBL -Institute for Health Research and Development
Principal Investigator: Sheick O Coulibaly, MD Laboratoire National de Sante Publique
  More Information

Additional Information:
Responsible Party: Brian Greenwood, Professor, London School of Hygiene and Tropical Medicine Identifier: NCT00140517     History of Changes
Other Study ID Numbers: HSR/DD/677-01/DG-CM/624-02
Study First Received: August 31, 2005
Last Updated: January 11, 2017

Keywords provided by London School of Hygiene and Tropical Medicine:
Plasmodium falciparum

Additional relevant MeSH terms:
Birth Weight
Protozoan Infections
Parasitic Diseases
Body Weight
Signs and Symptoms
Fanasil, pyrimethamine drug combination
Antiprotozoal Agents
Antiparasitic Agents
Anti-Infective Agents
Anti-Infective Agents, Urinary
Renal Agents
Folic Acid Antagonists
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antirheumatic Agents processed this record on May 23, 2017